RNS Number : 6175A
Arecor Therapeutics PLC
24 September 2025
Arecor Therapeutics plc
("Arecor" or the "Company")
Notice of Interim Results
Cambridge, UK, 24 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, will announce its interim results for the six months ended 30 June on Thursday 25 September 2025.
Dr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host a webcast for analysts and institutional investors at 3pm UK time on Thursday 25 September 2025. To register, please contact arecor@vigoconsulting.com. A copy of the interim results presentation will be released after the meeting on the Company website at www.arecor.com.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc Dr Sarah Howell, Chief Executive Officer David Ellam, Chief Financial Officer
+44 (0) 1223 426060 info@arecor.com
Singer Capital Markets Advisory LLP (NOMAD and Broker)
+44 (0) 20 7496 3000
Phil Davies, Sam Butcher
Vigo ConsultingMelanie Toyne-Sewell, Rozi Morris
+44 (0) 20 7390 0230 arecor@vigoconsulting.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat™, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin which is being co-developed with a US Automated Insulin Delivery pump device partner. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORFIFLTALISFIE
